- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Snapshot for Celgene Corp (CELG)
| Open: | 118.2800 | Day's Range: | 117.7235 - 120.4500 | Volume: | 1,827,925 |
|---|---|---|---|---|---|
| Previous Close: | 117.7000 | 52wk Range: | 58.5300 - 131.8190 | 1-Yr Rtn: | +77.82% |
Key Statistics for CELG
| Current P/E Ratio (ttm) | 29.1261 |
|---|---|
| Estimated P/E(12/2013) | 20.9916 |
| Relative P/E vs. SPX | 1.8034 |
| Earnings Per Share (USD) (ttm) | 4.1282 |
| Est. EPS (USD) (12/2013) | 5.7280 |
| Est. PEG Ratio | 0.8886 |
| Market Cap (M USD) | 50,154.80 |
| Shares Outstanding (M) | 417.12 |
| 30 Day Average Volume | 3,158,923 |
| Price/Book (mrq) | 9.0509 |
| Price/Sale (ttm) | 8.9800 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CELG
Company Profile & Key Executives for CELG
Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
| Robert J HuginChairman/President/CEO | Jacqualyn A FouseExec VP/CFO |
| Thomas O DanielExec VP/Pres:Research | Lawrence V SteinExec VP/Secy/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CELG News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page